You are here: Home pathway Area of law pathway Lymerix

Defective Drugs Lawyers and Attorneys Legal Help


Lymerix is a genetically engineered vaccine that contains lipoprotein OspA, an outer surface protein of the causative bacterium, Borrelia burgdorferi. When infected ticks bite individuals who have been vaccinated with LYMErix, the vaccine-induced antibodies are taken up by the tick and interact with the Borrelia burgdorferi in the midgut of the tick, thus preventing transmission of the organism to the host.


The most common tick transmitted disease in the United States is LYME disease. It is most often contracted during warm-weather months. Lyme disease usually begins with a skin rash called erythema migrans (EM), often accompanied by flu-like symptoms of fever, malaise, fatigue, and muscle and joint pains. The characteristic skin lesion where the bite occurs is a flat or raised red area that expands, often with clearing at the center, to a diameter of up to 20 inches. However, it does not always occur, which can make the diagnosis more tricky, particularly when the patient is not aware of having been bitten by a tick. Other early signs can include small skin lesions, facial nerve paralysis, lymphocytic meningitis, and heart-rhythm disturbances.


Wheezing or some trouble in breathing,
Swelling of the face, lips, eyelids.
Severe skin rash

Muscle or joint aches
Low fever
Feeling of tiredness

Find a Lymerix Lawyer